Stock events for Sunshine Biopharma, Inc. (SBFM)
Sunshine Biopharma's stock price has declined over the past year. Key events include a potential reverse stock split, COO stepping down, shareholder approval of the board and expanded equity plan, third-quarter EPS worse than analyst estimates, regulatory win to market Domperidone in Canada, launch of Doxycycline and Pravastatin, investment in Bitcoin, launch of NIOPEG, and a delay in the Adva-27a program due to unfavorable lab results.
Demand Seasonality affecting Sunshine Biopharma, Inc.’s stock price
There is no explicit information available that indicates significant demand seasonality for Sunshine Biopharma, Inc.'s products and services. The company's revenue primarily comes from generic prescription drugs in Canada, which generally provide recurring revenue.
Overview of Sunshine Biopharma, Inc.’s business
Sunshine Biopharma, Inc. is a pharmaceutical and biotechnology company focused on researching, developing, and commercializing medicines. Their business model combines a generics and biosimilars platform with a proprietary drug development program, operating through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. Major products include generic prescription drugs marketed through Nora Pharma Inc., biosimilars like NIOPEG, proprietary drug candidates such as Adva-27a, SBFM-PL4, and K1.1 mRNA, and a small portfolio of OTC nutritional supplements.
SBFM’s Geographic footprint
Sunshine Biopharma operates in the United States and Canada. The corporate office is in Fort Lauderdale, Florida, USA, and the company was incorporated in Colorado. Its Canadian subsidiary, Nora Pharma Inc., is headquartered in Pointe-Claire, Quebec, Canada.
SBFM Corporate Image Assessment
Sunshine Biopharma's brand reputation is mixed. Positive aspects include revenue growth, new product launches, proprietary drug development, and analyst endorsement. Negative aspects include profitability and cash flow issues, share dilution, drug development delays, and stock price performance. The strategic investment in Bitcoin could be viewed positively or negatively.
Ownership
Sunshine Biopharma has low institutional ownership, with institutions holding approximately 4.61% to 41.98% of the stock. Major institutional owners include Citadel Advisors Llc, Virtu Financial LLC, and Morgan Stanley. Individual insiders hold a notable percentage, with Malek Chamoun owning a significant portion of the company's shares.
